A brain implant that helps control severe epilepsy in adults may do the same for children who suffer from unrelenting seizures, new research suggests.
The study is one of the first to examine the responsive neurostimulation (RNS) system in children.
RNS has already been approved by the U.S. Food and Drug Administration for adult patients with drug-resistant epilepsy, but the research for safety and efficacy in children has been limited.
“As we expand use of RNS to children, it is critical to consider how to determine the lower age limit,” said study author Dr. Yasunori Nagahama, director of pediatric epilepsy surgery at Rutgers Robert Wood Johnson Medical School in New Jersey.
“In this study, there were two patients under 7 years at the time RNS was implanted, including a 3-year-old, who was the youngest reported patient to undergo RNS implantation,” he added.
Nagahama and his team looked at 35 children and young adults, ranging in age from 3 to 25, who were plagued by drug-resistant epilepsy and were treated with RNS. Afterwards, 84% of the patients saw a reduction in disabling seizures, including 18% who had a reduction of more than 90%, and 6% who achieved complete freedom from seizures.
RNS involves implanting a device (similar to a heart pacemaker) that sends electrical charges directly to the brain, stimulating it when needed to prevent seizures. This system is being increasingly used in pediatric centers to help control seizures.
Of those plagued by epileptic seizures, up to 40% don’t respond to medication, the study authors noted.
As an alternative to medication, RNS works by monitoring brainwave activity to detect developing seizures or any unusual electrical activity that may trigger seizures. The implanted device then delivers small pulses of stimulation to help the brainwaves return to normal.
“The findings suggest that responsive neurostimulation is an effective off-label surgical treatment of drug-resistant epilepsy in carefully selected pediatric patients,” Nagahama said. “However, more research on long-term efficacy and safety is needed to determine which patients will benefit most.”
The findings were published recently in the journal Neurosurgery.
Despite the positive findings, RNS does come with risk, according to two experts who were not involved with the study.
“The RNS device is implanted into the skull, and in very young children there may be a risk for complications related to ongoing skull growth,” said Dr. Keith Starnes, a pediatric epileptologist with the Mayo Clinic in Rochester, Minn. “Variability in skull growth and thickness should be considered on a case-by-case basis, and the potential benefits of neuromodulation weighed against the possibility of complications for an individual patient.”
Another caveat to consider for RNS is the battery life of the monitor, Starnes noted.
“The expected battery life for RNS is currently about five to nine years. For children who have longer expected remaining life spans than adults, this could mean several more skull surgeries for battery replacement,” he explained. “It is possible that this concern may be obviated in the future by advances in battery life and other technologies, but for now this is an important consideration.”
Still, the findings suggest RNS is an effective, safe and well-tolerated treatment that can reduce the number of disabling seizurs in children with epilepsy. But pediatric specialists should carefully select patients, who can be as young as 3, to determine if the implant is a suitable treatment for their condition.
ARTICLE SOURCES: Rutgers University, news release, Jan. 5, 2022; Keith Starnes, MD, member, Epilepsy Society, and pediatric epileptologist, Mayo Clinic, Rochester, Minn.; Aparna Polavarapu, MD, pediatric epilepsy specialist and assistant professor, Montefiore Health System, New York City; Neurosurgery, December 2021
EpilepsyU Source: By Adam Myer kulr8.com – This article originally ran on consumer/healthday.com.